-
公开(公告)号：US09206425B2
公开(公告)日：2015-12-08
申请号：US14235482
申请日：2012-07-24
Applicant: Ta-Yuan Chang , Catherine C. Y. Chang , Maximillian A. Rogers
Inventor： Ta-Yuan Chang , Catherine C. Y. Chang , Maximillian A. Rogers
IPC: C12N15/11 , C12N15/113 , A61K31/7105 , A61K31/713
CPC classification number: C12N15/113 , A61K31/7105 , A61K31/713 , C12N15/1137 , C12N2310/14 , C12N2310/141 , C12Y203/01009
Abstract: The present invention includes methods for treating Niemann-Pick Type C disease through administration of inhibitors of acyl-coenzyme A:cholesterol acyltransferase 1 (ACAT1). ACAT inhibitors are used to treat symptoms of Niemann-Pick Type C disease and prolong survival of patients with the disease, either alone or in combination with other treatments.
Abstract translation: 本发明包括通过施用酰基辅酶A：胆固醇酰基转移酶1（ACAT1）的抑制剂治疗尼曼 - 皮克型C型疾病的方法。 ACAT抑制剂用于治疗尼曼 - 皮克C型疾病的症状，并且可以单独或与其他治疗组合延长患有该疾病的患者的存活。
-
2.发明授权Methods for identifying allosteric and other novel acyl-coenzyme A:cholesterol acyltransferase inhibitors 失效用于鉴别变构和其他新型酰基辅酶A：胆固醇酰基转移酶抑制剂的方法公开(公告)号：US08673587B2
公开(公告)日：2014-03-18
申请号：US13639141
申请日：2011-05-03
Applicant: Ta-Yuan Chang , Catherine C. Y. Chang
Inventor： Ta-Yuan Chang , Catherine C. Y. Chang
IPC: C12Q1/48
CPC classification number: C12Q1/48 , G01N2333/91057 , G01N2500/02
Abstract: The present invention is a method for identifying compounds that are allosteric and/or other novel ACAT inhibitors that is based on the novel finding that pregnenolone is a substrate for ACAT; esterification of pregnenolone by ACAT is dramatically activated when cholesterol is present in the assay. The method comprises measuring the esterification of pregnenolone by ACAT under two different conditions: with cholesterol, or without cholesterol. This method can be used to test and categorize various candidate ACAT inhibitors as allosteric or other novel ACAT inhibitors, or it can be used in high-throughput screening for identifying such ACAT inhibitors.
Abstract translation: 本发明是一种鉴别化合物的方法，该化合物是基于新戊酸烯醇酮是ACAT底物的新发现的变构型和/或其它新型ACAT抑制剂。 当胆固醇存在于测定中时，ACAT的孕烯醇酮酯化剧烈活化。 该方法包括通过ACAT在两种不同条件下测定孕烯醇酮的酯化：用胆固醇或不含胆固醇。 该方法可用于测试和分类各种候选ACAT抑制剂作为变构或其他新型ACAT抑制剂，或者可用于高通量筛选鉴定此类ACAT抑制剂。
-
3.发明授权公开(公告)号：US07028277B2
公开(公告)日：2006-04-11
申请号：US10326500
申请日：2002-12-20
Applicant: Victor C. Y. Chang , Chung-Shi Chiang , Chien-Wen Chen , Harry Chuang , Hsin-Yi Lee , Yu-Tai Chia
Inventor： Victor C. Y. Chang , Chung-Shi Chiang , Chien-Wen Chen , Harry Chuang , Hsin-Yi Lee , Yu-Tai Chia
CPC classification number: G06F17/5036
Abstract: Each of a method for determining a parasitic capacitance and an apparatus for determining the parasitic capacitance provides for an experimental correlation within a parasitic capacitance model of a series of conductor layer nominal dimensions and spacings with a process related deviation to provide a series of conductor layer actual dimensions and spacings. The method and the apparatus further provide for determining the parasitic capacitance while employing the conductor layer actual dimensions and spacings. The parasitic capacitance is thus determined with enhanced accuracy.
Abstract translation: 用于确定寄生电容的方法和用于确定寄生电容的装置中的每一个提供了在一系列导体层标称尺寸和间隔的寄生电容模型内的与过程相关偏差的实验相关性，以提供一系列导体层实际 尺寸和间距。 该方法和装置进一步提供了在采用导体层的实际尺寸和间距的同时确定寄生电容。 因此，寄生电容的精度提高。
-
4.发明授权公开(公告)号：US06854100B1
公开(公告)日：2005-02-08
申请号：US10228496
申请日：2002-08-27
Applicant: Harry Chuang , Victor C. Y. Chang , Yung-Shun Chen , Shang Y. Hou
Inventor： Harry Chuang , Victor C. Y. Chang , Yung-Shun Chen , Shang Y. Hou
IPC: G06F17/50 , H01L21/66 , H01L21/768 , H01L21/82
CPC classification number: G06F17/5036
Abstract: A new method to determine a parameter of a damascene interconnect in an integrated circuit device is achieved. Drawn dimensions and local pattern density of a damascene interconnect are extracted in an integrated circuit device. A parameter of the damascene interconnect is calculating using the drawn dimensions and the local pattern density to select a per unit value from a set of per unit values measured over a range of drawn dimension and pattern density combinations. The method may be used to improve the accuracy of extracted damascene metal line resistance and parasitic capacitance.
Abstract translation: 实现了一种确定集成电路器件中的镶嵌互连参数的新方法。 在集成电路器件中提取镶嵌互连的拉丝尺寸和局部图案密度。 大马士革互连的参数是使用绘制的尺寸和局部图案密度来计算，以从在拉伸尺寸和图案密度组合的范围上测量的每单位值的集合中选择每单位值。 该方法可用于提高提取的镶嵌金属线电阻和寄生电容的精度。
-
公开(公告)号：US5834283A
公开(公告)日：1998-11-10
申请号：US509187
申请日：1995-07-31
Applicant: Ta-Yuan Chang , Catherine C. Y. Chang
Inventor： Ta-Yuan Chang , Catherine C. Y. Chang
CPC classification number: C12N15/8509 , C12N9/1029 , A01K2207/15 , A01K2217/00 , A01K2217/05 , A01K2217/075 , A01K2227/10 , A01K2227/30 , A01K2267/02 , A01K2267/03 , A01K2267/0362 , A61K38/00
Abstract: This invention pertains to purified, biologically active acyl coenzyme A: cholesterol acyltransferase (ACAT) and to nucleic acid (DNA or RNA) encoding acyl coenzyme A:cholesterol acyltransferase. The nucleic acid, or a fragment thereof, may be ligated with an expression vector and transfected into cells to express acyl coenzyme A:cholesterol acyltransferase activity in intact cells and in cell-free extracts.
Abstract translation: 本发明涉及纯化的生物活性酰基辅酶A：胆固醇酰基转移酶（ACAT）和编码酰基辅酶A：胆固醇酰基转移酶的核酸（DNA或RNA）。 核酸或其片段可以与表达载体连接并转染到细胞中以在完整细胞和无细胞提取物中表达酰基辅酶A：胆固醇酰基转移酶活性。
-
Patent Agency Ranking6.发明授权Cloned gene encoding acylcoenzyme A: cholesterol acyltransferase (ACAT) 失效编码酰基辅酶A的克隆基因：胆固醇酰基转移酶（ACAT）
公开(公告)号：US5484727A
公开(公告)日：1996-01-16
申请号：US121057
申请日：1993-09-10
Applicant: Ta-Yuan Chang , Catherine C. Y. Chang
Inventor： Ta-Yuan Chang , Catherine C. Y. Chang
CPC classification number: C12N15/8509 , C12N9/1029 , A01K2207/15 , A01K2217/00 , A01K2217/05 , A01K2217/075 , A01K2227/10 , A01K2227/30 , A01K2267/02 , A01K2267/03 , A01K2267/0362 , A61K38/00
Abstract: This invention pertains to purified, biologically active acyl coenzyme A: cholesterol acyltransferase (ACAT) and to nucleic acid (DNA or RNA) encoding acyl coenzyme A: cholesterol acyltransferase. The nucleic acid, or a fragment thereof, may be ligated with an expression vector and transfected into cells to express acyl coenzyme A: cholesterol acyltransferase activity in intact cells and in cell-free extracts.
Abstract translation: 本发明涉及纯化的生物活性酰基辅酶A：胆固醇酰基转移酶（ACAT）和编码酰基辅酶A：胆固醇酰基转移酶的核酸（DNA或RNA）。 核酸或其片段可以与表达载体连接并转染到细胞中以在完整细胞和无细胞提取物中表达酰基辅酶A：胆固醇酰基转移酶活性。
-
7.发明授权Method for selectively inhibiting the activity of ACAT1 in the treatment of alzheimer's disease 有权选择性抑制ACAT1在治疗阿尔茨海默病中的活性的方法公开(公告)号：US08802646B2
公开(公告)日：2014-08-12
申请号：US13605206
申请日：2012-09-06
Applicant: Ta-Yuan Chang , Catherine C. Y. Chang , Elena Bryleva , Stephanie Murphy , Maximillian A. Rogers
Inventor： Ta-Yuan Chang , Catherine C. Y. Chang , Elena Bryleva , Stephanie Murphy , Maximillian A. Rogers
CPC classification number: A61K31/255 , A61K31/00 , A61K31/70 , A61K31/7105 , A61K31/713 , C12N15/1137 , C12N2310/14 , C12N2310/141 , C12Y203/01009
Abstract: The present invention features methods for decreasing the size and density of amyloid plaques, decreasing cognitive decline associated with amyloid pathology, and treating Alzheimer's disease by selectively inhibiting the activity of Acyl-CoA:Cholesterol Acyltransferase 1, but not Acyl-CoA:Cholesterol Acyltransferase 2.
Abstract translation: 本发明的特征在于降低淀粉样蛋白斑块的尺寸和密度，降低与淀粉样蛋白病理学相关的认知衰退的方法，并通过选择性抑制酰基辅酶A：胆固醇酰基转移酶1但不是酰基辅酶A：胆固醇酰基转移酶2的活性来治疗阿尔茨海默氏病 。
-
公开(公告)号：US20130239239A1
公开(公告)日：2013-09-12
申请号：US13414679
申请日：2012-03-07
IPC: G01N33/574 , C12Q1/02 , C12N15/85 , C12N5/10 , A61K39/395 , C07H21/04 , C07K16/18 , A01K67/027 , A61P35/00 , C12Q1/68 , A61K31/7088
CPC classification number: G01N33/57484 , A01K2207/12 , A01K2217/072 , A01K2227/105 , A01K2267/0331 , A61K31/7088 , C12Q1/6886 , C12Q2600/118 , C12Q2600/156 , G01N33/5029 , G01N2500/10 , G01N2800/7028
Abstract: The present invention provides LMCD1 cancer markers, and methods, compositions, and kits for their use. The invention also provides expression vectors, host cells, and transgenic animals comprising one or more LMCD1 mutations, and methods for their use in characterizing, diagnosing, and treating cancers, and for identifying potential therapeutics. The invention also provides cancer therapeutics.
Abstract translation: 本发明提供LMCD1癌症标志物，以及用于其使用的方法，组合物和试剂盒。 本发明还提供了表达载体，宿主细胞和包含一种或多种LMCD1突变的转基因动物，以及用于表征，诊断和治疗癌症以及鉴定潜在治疗剂的方法。 本发明还提供癌症治疗剂。
-
9.发明授权Method of selectively inhibiting the activity of ACAT1 in the treatment of Alzheimer's disease 有权选择性抑制ACAT1在治疗阿尔茨海默病中的活性的方法公开(公告)号：US08466121B2
公开(公告)日：2013-06-18
申请号：US13072915
申请日：2011-03-28
Applicant: Ta-Yuan Chang , Catherine C. Y. Chang
Inventor： Ta-Yuan Chang , Catherine C. Y. Chang
CPC classification number: A61K31/255 , A61K31/00 , A61K31/70
Abstract: The present invention features methods for decreasing the size and density of amyloid plaques, decreasing cognitive decline associated with amyloid pathology, and treating Alzheimer's disease by selectively inhibiting the activity of Acyl-CoA:Cholesterol Acyltransferase 1, but not Acyl-CoA:Cholesterol Acyltransferase 2.
Abstract translation: 本发明的特征在于降低淀粉样蛋白斑块的尺寸和密度，降低与淀粉样蛋白病理学相关的认知衰退的方法，并通过选择性抑制酰基辅酶A：胆固醇酰基转移酶1但不是酰基辅酶A：胆固醇酰基转移酶2的活性来治疗阿尔茨海默氏病 。
-
公开(公告)号：US20070266360A1
公开(公告)日：2007-11-15
申请号：US11688692
申请日：2007-03-20
Applicant: Yi-Kan Cheng , Ke-Ying Su , Victor C. Y. Chang
Inventor： Yi-Kan Cheng , Ke-Ying Su , Victor C. Y. Chang
IPC: G06F17/50
CPC classification number: G06F17/5081 , G06F2217/12 , Y02P90/265
Abstract: An integrated circuit (IC) design method includes providing a design layout defined in a plurality of grids; simulating a chemical mechanical polishing (CMP) process to an IC substrate with a patterned structure defined by the design layout, generating a dielectric thickness and a metal thickness on one of the plurality of grids; extracting a capacitance based on the dielectric thickness on the one of the plurality of grids; and extracting a resistance based on the metal thickness on the one of the plurality of grids.
Abstract translation: 集成电路（IC）设计方法包括提供在多个网格中定义的设计布局; 模拟化学机械抛光（CMP）工艺到具有由设计布局限定的图案化结构的IC衬底，在所述多个栅格之一上产生电介质厚度和金属厚度; 基于所述多个栅格中的所述一个栅极上的电介质厚度提取电容; 以及基于所述多个网格中的所述一个网格上的金属厚度提取电阻。
-
-
-
-
-
-
-
-
-
Search Results
17
records
(took 0.021 seconds)
